Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 1-Year Low – Should You Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) reached a new 52-week low during trading on Monday. The stock traded as low as $13.43 and last traded at $13.43, with a volume of 10,087 shares traded. The stock had previously closed at $14.62.

Wall Street Analyst Weigh In

Several analysts have commented on the company. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citizens Jmp initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price target for the company. William Blair assumed coverage on shares of Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Citigroup started coverage on Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to data from MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and an average target price of $43.44.

Read Our Latest Stock Report on AAPG

Ascentage Pharma Group International Stock Down 8.6%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The company has a fifty day moving average price of $15.36 and a two-hundred day moving average price of $19.61.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million during the quarter. Equities analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Read More

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.